Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hawkins

Showing results (511-520 of 570) with videos related to

Pageof 57
Sort By:
JCO Clinical Cancer Informatics|October 18, 2021
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer ResearchAlejandro Plana, Brian Furner, Monica Palese, et al.
The Lancet. Oncology|December 2, 2019
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective studySheri L Spunt, Lynn Million, Yueh-Yun Chi, et al.
Nature Microbiology|January 9, 2019
Enabling genetic analysis of diverse bacteria with Mobile-CRISPRiJason M Peters, Byoung-Mo Koo, Ramiro Patino, et al.
Circulation. Genomic and Precision Medicine|March 28, 2025
DNA Damage Response and Repair Genes and Anthracycline-Induced Cardiomyopathy in Childhood Cancer Survivors: A Report From the Children's Oncology Group and the Childhood Cancer Survivor StudyXuexia Wang, Purnima Singh, Romina B Cejas, et al.
JCO Precision Oncology|September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)Margaret E Macy, Rajen Mody, Joel M Reid, et al.
EJC Paediatric Oncology|October 13, 2023
Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspectiveKris Ann P Schultz, Murali Chintagumpala, Jin Piao, et al.
Journal of Clinical Medicine|April 30, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task ForceHolly L Pacenta, Wendy Allen-Rhoades, David Langenau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH TrialOlive S Eckstein, Carl E Allen, P Mickey Williams, et al.
Journal of the National Cancer Institute|December 29, 2020
Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology GroupHe Li, Saumya D Sisoudiya, Bailey A Martin-Giacalone, et al.
JCO Precision Oncology|June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialKieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
Pageof 57

Showing results (511-520 of 570) with videos related to

Sort By:
Pageof 57
JCO Clinical Cancer Informatics|October 18, 2021
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer ResearchAlejandro Plana, Brian Furner, Monica Palese, et al.
The Lancet. Oncology|December 2, 2019
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective studySheri L Spunt, Lynn Million, Yueh-Yun Chi, et al.
Nature Microbiology|January 9, 2019
Enabling genetic analysis of diverse bacteria with Mobile-CRISPRiJason M Peters, Byoung-Mo Koo, Ramiro Patino, et al.
Circulation. Genomic and Precision Medicine|March 28, 2025
DNA Damage Response and Repair Genes and Anthracycline-Induced Cardiomyopathy in Childhood Cancer Survivors: A Report From the Children's Oncology Group and the Childhood Cancer Survivor StudyXuexia Wang, Purnima Singh, Romina B Cejas, et al.
JCO Precision Oncology|September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)Margaret E Macy, Rajen Mody, Joel M Reid, et al.
EJC Paediatric Oncology|October 13, 2023
Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspectiveKris Ann P Schultz, Murali Chintagumpala, Jin Piao, et al.
Journal of Clinical Medicine|April 30, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task ForceHolly L Pacenta, Wendy Allen-Rhoades, David Langenau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH TrialOlive S Eckstein, Carl E Allen, P Mickey Williams, et al.
Journal of the National Cancer Institute|December 29, 2020
Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology GroupHe Li, Saumya D Sisoudiya, Bailey A Martin-Giacalone, et al.
JCO Precision Oncology|June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialKieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
Pageof 57